Monoclonal antibodies against calcitonin gene-related peptide or its receptor (mAB-CGRP) offer improvements over available drugs in migraine prophylaxis. Safety and persistence are essential to achieve disease management goals.

AIM AND OBJECTIVES
To assess the persistence and safety of mAB-CGRP in patients with chronic migraine in clinical practice.

MATERIAL AND METHODS

- **Observational retrospective single-center study**
  - December 2019 - September 2021
  - All patients with chronic migraine
  - Treated at least 1 month with mAB-CGRP

- **Variables collected from clinical history**
  - Age and sex
  - Number migraines/month and previous treatments
  - mAB-CGRP type, start and discontinuation date
  - Reasons for discontinuation
  - mAB-CGRP switching
  - Adverse effects

- **Variables**
  - *Primary outcome:* first- and second-line persistence
  - Patients treated less than 3 months were excluded
  - *Secondary outcomes:* adverse effect and reasons of discontinuation
  - Kaplan-Meier survival curves: to analyze persistence
  - Log-rank test: for comparison

RESULTS

94 patients with chronic migraine treated with mAbs-CGRP

- **84.04% women**
- **Median age:** 50 years (44-58)
- **Median migraines/month:** 14 (10-20)

<table>
<thead>
<tr>
<th>Treatment line</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
</tr>
</thead>
<tbody>
<tr>
<td>mAB-CGRP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>Patients</td>
<td>Discont</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>Patients</td>
<td>Discont</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Patients</td>
<td>Discont</td>
<td>8</td>
</tr>
<tr>
<td>Erenumab</td>
<td>42</td>
<td>17</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>19</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Galcanezumab</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>19</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Fremanezumab</td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>19</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

**Main reason of discontinuation:** ineffectiveness (80.77%)

Other reasons: treatment ending, pregnancy, loss of follow-up and patient’s decision

**Overall persistence**
- 1st line: 67.0%
- 2nd line: 52.1%

12-month overall persistence rates (p>0.05)

**1st line**
- Erenumab
galcanezumab
fremanezumab
- Median (months): 13.4
- Not reached

**2nd line**
- Median (months): 11.8-18.8

**SIDE EFFECTS**
- *Botulinum toxin: 100.0%
- Tricyclic antidepressants: 90.4%
- Neuromodulators: 88.3%
- Calcium-channel blockers: 64.9%
- Beta-blockers: 59.6%
- Others: 21.3%

- **Adverse effects that appeared in 21 patients**
  - Constipation: 8.51%
  - Injection-related headache: 5.32%
  - Dizziness: 4.26%
  - Injections: 4.26%
  - Vertigo: 2.13%
  - Pruritus: 2.13%

**Reasons for discontinuation**
- *Others: weight loss, insomnia and alopecia*

CONCLUSIONS

First- and second-line treatment with mAB-CGRP showed similar levels of persistence. First-line erenumab and galcanezumab also demonstrated the same results.

The frequency of adverse effects is lower than reported in clinical trials, so we can conclude that mAB-CGRPs are safe drugs.